
Laverock reports positive data from oncology programmes
Laverock Therapeutics has reported in vivo functional milestones across its T-cell and macrophage oncology programmes as it advances its lead programme towards clinic. Data from ovarian cancer models, presented at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting in May, demonstrated the company’s… Read More















